|
1
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Sun K, Zheng R, Zeng H, Zhang S,
Xia C, Yang Z, Li H, Zou X and He J: Cancer incidence and mortality
in China, 2014. Chin J Cancer Res. 30:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davidson MR, Gazdar AF and Clarke BE: The
pivotal role of pathology in the management of lung cancer. J
Thorac Dis. 5 (Suppl 5):S463–S478. 2013.PubMed/NCBI
|
|
4
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gridelli C, Rossi A and Maione P:
Treatment of non-small-cell lung cancer: State of the art and
development of new biologic agents. Oncogene. 22:6629–6638. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang G, Shu XO, Chow WH, Zhang X, Li HL,
Ji BT, Cai H, Wu S, Gao YT and Zheng W: Soy food intake and risk of
lung cancer: Evidence from the shanghai women's health study and a
meta-analysis. Am J Epidemiol. 176:846–855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Benassayag C, Perrot-Applanat M and Ferre
F: Phytoestrogens as modulators of steroid action in target cells.
J Chromatogr B Analyt Technol Biomed Life Sci. 777:233–248. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andres S, Abraham K, Appel KE and Lampen
A: Risks and benefits of dietary isoflavones for cancer. Crit Rev
Toxicol. 41:463–506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng F, Wang R, Zhang Y, Zhao Z, Zhou W,
Chang Z, Liang H, Zhao W, Qi L, Guo Z and Gu Y: Differential
expression analysis at the individual level reveals a lncRNA
prognostic signature for lung adenocarcinoma. Mol Cancer.
16:982017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mu M, Niu W, Zhang X, Hu S and Niu C:
LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively
binding with miR-619-5p to regulate CUEDC2 expression and the
PTEN/AKT/p21 pathway. Oncogene. 39:6879–6892. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu X, Wang D, Lin Q, Wu G, Yuan S, Ye F
and Fan Q: Screening key lncRNAs for human rectal adenocarcinoma
based on lncRNA-mRNA functional synergistic network. Cancer Med.
8:3875–3891. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang
Y, Jia L, Li S; Cancer Genome Atlas Research Network, ; Xie W and
Yang D: lncRNA epigenetic landscape analysis identifies EPIC1 as an
oncogenic lncRNA that interacts with MYC and promotes cell-cycle
progression in cancer. Cancer Cell. 33:706–720. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hauptman N and Glavač D: Long non-coding
RNA in cancer. Int J Mol Sci. 14:4655–4669. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bao Z, Yang Z, Huang Z, Zhou Y, Cui Q and
Dong D: LncRNADisease 2.0: An updated database of long non-coding
RNA-associated diseases. Nucleic Acids Res. 47:D1034–D1037. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen
X, Zhang Q, Yan G and Cui Q: LncRNADisease: A database for
long-non-coding RNA-associated diseases. Nucleic Acids Res.
41:D983–D986. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tokgun O, Tokgun PE, Inci K and Akca H:
lncRNAs as potential targets in small cell lung cancer:
MYC-dependent regulation. Anticancer Agents Med Chem. 20:2074–2081.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu T, Wang Y, Chen D, Liu J and Jiao W:
Potential clinical application of lncRNAs in non-small cell lung
cancer. Onco Targets Ther. 11:8045–8052. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lai XN, Li J, Tang LB, Chen WT, Zhang L
and Xiong LX: miRNAs and LncRNAs: Dual roles in TGF-β
signaling-regulated metastasis in lung cancer. Int J Mol Sci.
21:11932020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang M, Ma X, Zhu C, Guo L, Li Q, Liu M
and Zhang J: The prognostic value of long non coding RNAs in non
small cell lung cancer: A meta-analysis. Oncotarget. 7:81292–81304.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Patterson TA, Lobenhofer EK,
Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, Fang H, Kawasaki ES,
Hager J, Tikhonova IR, et al: Performance comparison of one-color
and two-color platforms within the microarray quality control
(MAQC) project. Nat Biotechnol. 24:1140–1150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci U S A. 95:14863–14868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li QW, Ma L, Qiu B, Yang H, Zhu YJ, Qiang
MY, Liu SR, Chen NB, Guo JY, Cai LZ, et al: Differential expression
profiles of long noncoding RNAs in synchronous multiple and
solitary primary esophageal squamous cell carcinomas: A microarray
analysis. J Cell Biochem. Oct 15–2018.(Epub ahead of print).
|
|
23
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gong WJ, Peng JB, Yin JY, Li XP, Zheng W,
Xiao L, Tan LM, Xiao D, Chen YX, Li X, et al: Association between
well-characterized lung cancer lncRNA polymorphisms and
platinum-based chemotherapy toxicity in Chinese patients with lung
cancer. Acta Pharmacol Sin. 38:581–590. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao T, Jin F, Li J, Xu Y, Dong H, Liu Q,
Xing P, Zhu G, Xu H and Miao Z: Dietary isoflavones or
isoflavone-rich food intake and breast cancer risk: A meta-analysis
of prospective cohort studies. Clin Nutr. 38:136–145. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tse G and Eslick GD: Soy and isoflavone
consumption and risk of gastrointestinal cancer: A systematic
review and meta-analysis. Eur J Nutr. 55:63–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wada K, Tsuji M, Tamura T, Konishi K,
Kawachi T, Hori A, Tanabashi S, Matsushita S, Tokimitsu N and
Nagata C: Soy isoflavone intake and stomach cancer risk in Japan:
From the Takayama study. Int J Cancer. 137:885–892. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zaheer K and Humayoun AM: An updated
review of dietary isoflavones: Nutrition, processing,
bioavailability and impacts on human health. Crit Rev Food Sci
Nutr. 57:1280–1293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Applegate C, Rowles J, Ranard K, Jeon S
and Erdman J: Soy consumption and the risk of prostate cancer: An
updated systematic review and meta-analysis. Nutrients. 10:402018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Woo HD and Kim J: Dietary flavonoid intake
and risk of stomach and colorectal cancer. World J Gastroentero.
19:1011–1019. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nachvak SM, Moradi S, Anjom-Shoae J,
Rahmani J, Nasiri M, Maleki V and Sadeghi O: Soy, soy isoflavones,
and protein intake in relation to mortality from all causes,
cancers, and cardiovascular diseases: A systematic review and
dose-response meta-analysis of prospective cohort studies. J Acad
Nutr Diet. 119:1483–1500. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Khan N and Mukhtar H: Dietary agents for
prevention and treatment of lung cancer. Cancer Lett. 359:155–164.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pan W: A comparative review of statistical
methods for discovering differentially expressed genes in
replicated microarray experiments. Bioinformatics. 18:546–554.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu Z, Fan C, Oh DS, Marron JS, He X,
Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The
molecular portraits of breast tumors are conserved across
microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu X, Ravindranath L, Tran N, Petrovics G
and Srivastava S: Regulation of apoptosis by a prostate-specific
and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell
Biol. 25:135–141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long noncoding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai M, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xue X, Yang YA, Zhang A, Fong K, Kim J,
Song B, Li S, Zhao JC and Yu J: LncRNA HOTAIR enhances ER signaling
and confers tamoxifen resistance in breast cancer. Oncogene.
35:2746–2755. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kazemzadeh M, Safaralizadeh R and Orang
AV: LncRNAs: Emerging players in gene regulation and disease
pathogenesis. J Genet. 94:771–784. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang X, Liang W, Liu J, Zang X, Gu J, Pan
L, Shi H, Fu M, Huang Z, Zhang Y, et al: Long non-coding RNA UFC1
promotes gastric cancer progression by regulating miR-498/Lin28b. J
Exp Clin Cancer Res. 37:1342018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chi Y, Wang D, Wang J, Yu W and Yang J:
Long non-coding RNA in the pathogenesis of cancers. Cells.
8:10152019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen R, Li WX, Sun Y, Duan Y, Li Q, Zhang
AX, Hu JL, Wang YM and Gao YD: Comprehensive analysis of lncRNA and
mRNA expression profiles in lung cancer. Clin Lab. 63:313–320.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei MM and Zhou GB: Long non-coding RNAs
and their roles in non-small-cell lung cancer. Genomics Proteomics
Bioinformatics. 14:280–288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han Q, Lin X, Zhang X, Jiang G, Zhang Y,
Miao Y, Rong X, Zheng X, Han Y, Han X, et al: WWC3 regulates the
Wnt and Hippo pathways via dishevelled proteins and large tumour
suppressor 1, to suppress lung cancer invasion and metastasis. J
Pathol. 242:435–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shao L, Li H, Chen J, Song H, Zhang Y, Wu
F, Wang W, Zhang W, Wang F, Li H and Tang D: Irisin suppresses the
migration, proliferation, and invasion of lung cancer cells via
inhibition of epithelial-to-mesenchymal transition. Biochem Biophys
Res Commun. 485:598–605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bai X, Meng L, Sun H, Li Z, Zhang X and
Hua S: MicroRNA-196b inhibits cell growth and metastasis of lung
cancer cells by targeting Runx2. Cell Physiol Biochem. 43:757–767.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu G, Pei F, Yang F, Li L, Amin AD, Liu
S, Buchan JR and Cho WC: Role of autophagy and apoptosis in
non-small-cell lung cancer. Int J Mol Sci. 18:3672017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gan PP, Zhou YY, Zhong MZ, Peng Y, Li L
and Li JH: Endoplasmic reticulum stress promotes autophagy and
apoptosis and reduces chemotherapy resistance in mutant p53 lung
cancer cells. Cell Physiol Biochem. 44:133–151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu J, Su C, Zhao F, Tao J, Hu D, Shi A,
Pan J and Zhang Y: Paclitaxel promotes lung cancer cell apoptosis
via MEG3-P53 pathway activation. Biochem Biophys Res Commun.
504:123–128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu YH, Liu GH, Mei JJ and Wang J: The
preventive effects of hyperoside on lung cancer in vitro by
inducing apoptosis and inhibiting proliferation through Caspase-3
and P53 signaling pathway. Biomed Pharmacother. 83:381–391. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Goldar S, Khaniani MS, Derakhshan SM and
Baradaran B: Molecular mechanisms of apoptosis and roles in cancer
development and treatment. Asian Pac J Cancer Prev. 16:2129–2144.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang Y, Li Q, Wei S, Sun J, Zhang X, He
L, Zhang L, Xu Z and Chen D: ZNF143 suppresses cell apoptosis and
promotes proliferation in gastric cancer via ROS/p53 axis. Dis
Markers. 2020:58631782020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gupta A, Behl T, Heer HR, Deshmukh R and
Sharma PL: Mdm2-P53 interaction inhibitor with cisplatin enhances
apoptosis in colon and prostate cancer cells in-vitro. Asian Pac J
Cancer Prev. 20:3341–3351. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ellis HM and Horvitz HR: Genetic control
of programmed cell death in the nematode C. elegans. Cell.
44:817–829. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sarfstein R, Nagaraj K, LeRoith D and
Werner H: Differential effects of insulin and IGF1 receptors on ERK
and AKT subcellular distribution in breast cancer cells. Cells.
8:14992019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ma JB, Bai JY, Zhang HB, Jia J, Shi Q,
Yang C, Wang X, He D and Guo P: KLF5 inhibits STAT3 activity and
tumor metastasis in prostate cancer by suppressing IGF1
transcription cooperatively with HDAC1. Cell Death Dis. 11:4662020.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hu J, Liu X, Chi J, Che K, Feng Y, Zhao S,
Wang Z and Wang Y: Expressions of IGF-1, ERK, GLUT4, IRS-1 in
metabolic syndrome complicated with colorectal cancer and their
associations with the clinical characteristics of CRC. Cancer
Biomark. 21:883–891. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang YA, Sun Y, Palmer J, Solomides C,
Huang LC, Shyr Y, Dicker AP and Lu B: IGFBP3 modulates lung
tumorigenesis and cell growth through IGF1 signaling. Mol Cancer
Res. 15:896–904. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Furstenberger G and Senn HJ: Insulin-like
growth factors and cancer. Lancet Oncol. 3:298–302. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang H, Zhang C and Wu D: Activation of
insulin-like growth factor 1 receptor regulates the
radiation-induced lung cancer cell apoptosis. Immunobiology.
220:1136–1140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Brambilla E, Gazzeri S, Gouyer V and
Brambilla C: Mechanisms of lung oncogenesis. Rev Prat. 43:807–814.
1993.(In French). PubMed/NCBI
|
|
62
|
Wang LJ, Li QJ, Le Y, Ouyang HY, He MK, Yu
ZS, Zhang YF and Shi M: Prognostic significance of sodium-potassium
ATPase regulator, FXYD3, in human hepatocellular carcinoma. Oncol
Lett. 15:3024–3030. 2018.PubMed/NCBI
|
|
63
|
Velloso FJ, Bianco AF, Farias JO, Torres
NE, Ferruzo PY, Anschau V, Jesus-Ferreira HC, Chang TH, Sogayar MC,
Zerbini LF and Correa RG: The crossroads of breast cancer
progression: Insights into the modulation of major signaling
pathways. Onco Targets Ther. 10:5491–5524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chuang CH, Cheng TC, Leu YL, Chuang KH,
Tzou SC and Chen CS: Discovery of Akt kinase inhibitors through
structure-based virtual screening and their evaluation as potential
anticancer agents. Int J Mol Sci. 16:3202–3212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yu X, Yuan Y, Zhi X, Teng B, Chen X, Huang
Q, Chen Y, Guan Z and Zhang Y: Correlation between the protein
expression of A-kinase anchor protein 95, cyclin D3 and AKT and
pathological indicators in lung cancer tissues. Exp Ther Med.
10:1175–1181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim BM, Kim DH, Park JH, Surh YJ and Na
HK: Ginsenoside Rg3 inhibits constitutive activation of NF-kB
signaling in human breast cancer (MDA-MB-231) cells: ERK and akt as
potential upstream targets. J Cancer Prev. 19:23–30. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bellacosa A, Testa JR, Moore R and Larue
L: A portrait of AKT kinases: Human cancer and animal models depict
a family with strong individualities. Cancer Biol Ther. 3:268–275.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cheng JQ, Lindsley CW, Cheng GZ, Yang H
and Nicosia SV: The Akt/PKB pathway: Molecular target for cancer
drug discovery. Oncogene. 24:7482–7492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hirsch T, Marzo I and Kroemer G: Role of
the mitochondrial permeability transition pore in apoptosis. Biosci
Rep. 17:67–76. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Koo J, Cabarcas-Petroski S, Petrie JL,
Diette N, White RJ and Schramm L: Induction of proto-oncogene BRF2
in breast cancer cells by the dietary soybean isoflavone daidzein.
BMC Cancer. 15:9052015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Guo S, Wang Y, Li Y, Li Y, Feng C and Li
Z: Daidzein-rich isoflavones aglycone inhibits lung cancer growth
through inhibition of NF-kB signaling pathway. Immunol Lett.
222:67–72. 2020. View Article : Google Scholar : PubMed/NCBI
|
